ClinicalTrials.gg
RecruitingNCT05568498ProDUpdated May 8, 2026

Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease

A Phase 2 interventional study of Probiotic and Placebo in Parkinson Disease, Depression and PARKINSON DISEASE (Disorder), sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University of British Columbia · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Parkinson Disease by University of British Columbia — 7 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · University of British Columbia.

Planned enrollment
2nd of 13
60 · median 40
Started
2025
with 2 others
Phase 2
3 of 14
1 open now
Registered
5th of 14
by date

Among the 14 studies in Parkinson Disease by University of British Columbia, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 2, and was the 5th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 14 studies in Parkinson Disease by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by University of British Columbia, or all of them as a file.
02

Study summary

This study evaluates the use of an oral multi-strain probiotic in the treatment of depression in individuals with Parkinson's Disease. Participants will be randomized to either a 12-week multi-strain probiotic treatment or placebo intervention.

Read the detailed description

Parkinson's disease (PD) is a complex condition that carries a high burden of neuropsychiatric comorbidities. About a third of individuals living with PD have one or more depressive disorders, resulting in lower quality of life, greater care dependency, and increased caregiver burden. Gastrointestinal dysfunction is also very common in PD. Constipation is experienced by the vast majority of patients and often manifests years before onset of motor symptoms. Symptoms suggestive of irritable bowel syndrome (IBS) are also commonly found in PD. Increased intestinal permeability has been demonstrated in PD; impaired intestinal barrier function can lead to chronic systemic low-grade inflammation, which has been strongly associated with mood disorders. Several lines of evidence suggest a link between the gut microbiome and PD.

The microbiome has been linked to depression both in human and animal studies. Several studies have found beneficial effects of probiotics on mood disorders in non-PD populations, including stress and depressive behaviour in animal models, and sad mood reactivity and major depressive disorder (MDD) in humans.

In summary, given the high rate of depression in PD, the growing evidence that probiotics may improve depression and mood disorders in non-PD populations, and the strong links between the gut microbiome and PD, we will carry out a randomized, triple-blinded, placebo-controlled study into the use of a multi-strain probiotic to improve depression and PD.

Recruitment: Approximately 60 participants will be randomized to either the probiotic intervention arm or the placebo intervention arm. Participants will mainly be recruited from the Pacific Parkinson's Research Centre (PPRC) Movement Disorder Clinic at the University of British Columbia (UBC) in Vancouver.

Participants will receive a detailed description of the study and will need to provide informed consent for participation in the study. Participants will be screened for inclusion and exclusion criteria, which include completing screening questionnaires and reviewing medications/medical history.

Assessments: Clinical assessments of motor function, cognition and neuropsychiatric symptoms will be administered before the 12-week intervention phase, as well as following the 12-week intervention. Phone check-ins at weeks 4 and 8 during the intervention will be done to record adverse events and medication/lifestyle changes. Remote questionnaires will be sent to participants at every time point (visit 1, week 4 check-in, week 8 check-in, final visit). Blood samples and stool samples will be collected before and after the intervention. Blood (18mL) will be collected at both the first and last visits by lab staff qualified for blood drawing. Stool sample kits will be given to participants to collect at home (first sample returned via mail before start of intervention, second sample returned at final visit after intervention).

The primary outcome will be the difference between the probiotic vs. placebo groups in mean Inventory of Depressive Symptomatology - Clinician-Rated (IDS-C) and mean Beck Depression Inventory 2nd edition (BDI-II) pre-/post-intervention. The primary analysis will be based on intention-to-treat. For other secondary outcomes, the between-group difference analysis will be applied to the fatigue, anxiety, PD motor function, and quality of life scores pre/post intervention, respectively. PD severity will be monitored using Parts I-IV of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Participants will be given a study journal to record their intervention doses, number of bowel movements, use of laxatives, and adverse events daily. Adverse events, tolerability and drop-out rates will be registered and overall rates compared between the intervention groups. Furthermore, differences and changes in blood markers and microbiome composition will be assessed.

03

Conditions studied

  • Parkinson Disease
  • Depression
  • PARKINSON DISEASE (Disorder)

Keywords

  • Parkinsons Disease
  • Depression
  • Probiotics
  • Gut Microbiome
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of Parkinson's disease based on UK Brain Bank criteria
  2. Between the ages of 40-80 years
  3. Mild to Moderate PD (Hoehn and Yahr stage between 1-3 in the "ON" state)
  4. Mild to moderate depression (BDI-II score of 14-28 in the "ON" state)
  5. Women of must agree to use a medically approved method of (e.g., hormonal contraceptives, intrauterine devices, vasectomy/tubal litigation, barrier methods and double barrier method) and must have negative pregnancy test results at screening and baseline
  6. Willingness to maintain current physical activity levels during study period
  7. English proficiency

Exclusion criteria

Exclusion Criteria:

  1. Atypical Parkinsonism
  2. Active suicidality
  3. Active psychosis
  4. Cognitive score () of \< 21 in the "ON" state
  5. Severe depression (BDI-II score > 28 in the "ON" state)
  6. Probiotic, Saccharomyces boulardii and/or antibiotic use in the past 3 months (yogurt, kefir, and other probiotic-containing foods are allowed)
  7. The use of natural health products that affect depression (e.g., St. John's Wort, passion flower, gaba, 5-htp, kava, bacopa, efa's)
  8. Change in the schedule of concurrent psychotherapy or brain stimulation for the treatment of mood or anxiety disorders in the last 4 weeks
  9. Change in antidepressant or anxiolytic medication (including benzodiazepines) within the last 4 weeks
  10. Change in Parkinson's medication within the last 2 weeks
  11. Neurological disease other than PD, including Alzheimer's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, a brain tumour, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma
  12. A significant immune-compromised condition due to either a health condition or use of an immune suppressant (e.g., AIDS, lymphoma, chemotherapy treatment, patients undergoing long-term systemic or treatment)
  13. A known bleeding disorder
  14. Current illness (e.g., a cold or flu-like symptoms) and infections (e.g., hepatitis, , gastroenteritis, fungal, or parasitic infections)
  15. Allergy to corn starch or corn
  16. Concurrent treatment for Parkinson's disease with Duodopa
  17. Change in Deep Brain Stimulation (DBS) stimulation parameters in the last 4 weeks
  18. New onset of significant psychiatric symptoms following DBS procedure that are considered likely related
  19. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  20. Unstable medical conditions or serious disease/conditions (e.g., cancer undergoing active treatment, poorly controlled diabetes)
  21. Drug and/or substance abuse
  22. The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study. This includes any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a significant language barrier or cognitive impairment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Probiotic

    Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5\*10\^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10\^9 CFU/gram) per day.

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo

    Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    Oral probiotic delivered in powdered form.

    Also known as: Ecologic® BARRIER 849

  • Dietary supplementPlacebo

    Oral placebo delivered in powdered form.

06

What researchers measure

Primary outcomes

  1. Inventory of Depressive Symptomatology - Clinician-Rated (IDS-C)

    The Inventory for Depressive Symptomatology is a measure of depressive signs and symptoms administered by a trained clinician. The score range is 0-84 points, with a higher score indicating greater levels of depressive symptomatology.

    Time frame: 13 weeks

  2. Beck Depression Inventory, 2nd Edition (BDI-II)

    The Beck Depression Inventory is a self-reported 21-question multiple-choice self-report inventory on a scale from 0-63. A higher score indicates greater characteristic attitudes and symptoms of depression. BDI-II is also used as a screening item for mild to moderate depression for this study.

    Time frame: 13 weeks

  3. Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)

    QIDS-SR is a 16-item, self-administered questionnaire used to assess the severity of depressive symptoms over the past 7 days, based on DSM-IV criteria. QIDS-SR is a shortened version of IDS-C, but QIDS-SR is self-rated (filled in the form of a questionnaire) and IDS-C is clinician-rated (administered as a clinical assessment), so using both assessments allows us to incorporate both self-rated and clinician-rated measures. The score range is 0-27 points, with a higher score indicating greater levels of depressive symptomatology.

    Time frame: 13 weeks

Secondary outcomes

  1. Fatigue Severity Scale (FSS)

    The Fatigue Severity Scale is a self-reported 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders on a scale from 1 (strongly disagree) to 7 (strongly agree). The minimum score is 9 and the maximum score is 63. A higher score indicates greater fatigue severity.

    Time frame: 13 weeks

  2. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment test is a one-page, 30-point assessment administered by trained individuals that is used for detecting mild cognitive impairment and dementia. Score may range from 0-30 points and a lower score may indicate greater cognitive impairment.

    Time frame: 13 weeks

  3. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The Movement Disorder Society Unified Parkinson's Disease Rating Scale is a clinical assessment of motor and non-motor symptoms in individuals with Parkinson's Disease (PD). It consists of four subscales. Subscales 1, 3, and 4 are administered by a trained individual and subscale 2 is self-reported. Each item is rated from 0 to 4. The total score can range from 0-199, with a higher score indicating greater impairment in PD.

    Time frame: 13 weeks

  4. Parkinson's Anxiety Scale (PAS)

    The Parkinson's Anxiety Scale is a 12-point observer or patient-rated scale that has three subscales: persistent anxiety, episodic anxiety, and avoidance behaviour. It is rated using a Likert scale (0-4). Possible scores range from 0-48, with a higher score indicating greater severity of anxiety symptoms.

    Time frame: 13 weeks

  5. Parkinson's Disease Quality of Life Questionnaire (PDQ-39)

    The Parkinson's Disease Quality of Life Questionnaire is a self-reported questionnaire that assesses how often people affected by Parkinson's Disease (PD) experience difficulties across 8 dimensions of daily living. It consists of 39 items and is rated on a Likert scale (0-4). Each dimension's score can range from 0-100. A higher score indicates a worse quality of life.

    Time frame: 13 weeks

  6. Parkinson's Disease - Cognitive Rating Scale (PD-CRS)

    The Parkinson's Disease - Cognitive Rating Scale (PD-CRS) is a cognitive scale specifically designed to capture the whole spectrum of cognitive functions impaired over the course of Parkinson's Disease (PD). This battery is composed of a total of 9 tasks explicitly designed for a brief and separate scoring of: Frontal Subcortical tasks (sustained attention, working memory, alternating and action verbal fluency, clock drawing, immediate and delayed free recall verbal memory) and Posterior Cortical tasks (confrontation naming and clock copying).

    Time frame: 13 weeks

  7. Parkinson's Disease - Cognitive Functional Rating Scale (PD-CFRS)

    The PD-CFRS is a short Parkinson's Disease (PD) specific questionnaire, used to explore a wide range of functional aspects suspected to be sensitive to cognitive impairment in PD. All 12 questions explore, with some examples, whether or not the patient has had trouble performing specific activities in the past few weeks.

    Time frame: 13 weeks

07

Study locations

1 of 1 sites recruiting
  • Pacific Parkinson's Research Centre
    Vancouver, British Columbia V6T2B5, Canada
    Recruiting
    • Annie Kuan · Contactannie.kuan@ubc.ca · 604-827-0576
    • Silke Appel-Cresswell, MD, FRCPC · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 106 non-industry phase 2 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 35 months is close to that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2022
First posted
Oct 5, 2022
StartActual
Jan 20, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05568498
Responsible party
Silke Cresswell (Associate Professor, University of British Columbia) — Principal investigator
First posted
Oct 5, 2022
Start date
Jan 20, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 8, 2026

Study contacts

Matthew Leung, BSc
Contact
Matthew.Leung@ubc.ca
604-827-1905
Annie Kuan
Contact
annie.kuan@ubc.ca
604-827-0576

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion